This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos andLiving Beyond Breast Cancer, and is supported by Lilly.
